155891-93-3

Usage

Uses

Used in Agricultural and Horticultural Industries:
(3,5-Dichloro-4-hydroxy-phenyl)-carbamic acid tert-butyl ester is used as a herbicide for controlling weeds in various agricultural and horticultural crops. It helps to protect the crops from being overtaken by weeds, ensuring better growth and yield.
Used in Non-Crop Land Management:
(3,5-Dichloro-4-hydroxy-phenyl)-carbamic acid tert-butyl ester is also used as a herbicide on non-crop land to control the growth of unwanted plants and maintain the land for various purposes, such as construction sites or recreational areas.
Regulated Use:
Due to its moderate toxicity in humans and potential environmental contamination, the use of (3,5-Dichloro-4-hydroxy-phenyl)-carbamic acid tert-butyl ester is regulated in many countries. This is done to minimize its ecological and health impact and ensure that it is used responsibly and safely.

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 5930-28-9 4-amino-2,6-dichlorophenol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 691-64-5 di-tert-butyl oxalate 

Downstream Products

• 1098619-84-1 trifluoro-methanesulfonic acid 4-tert-butoxycarbonylamino-2,6-dichloro-phenyl ester 
• 852948-66-4 3,5-dichloro-4-(3'-iso-propyl-4'-methoxyphenoxy)phenylcarbamic acid tert-butyl ester 
• 409127-35-1 4-tert-butoxycarbonylamino-2,6-dichloro-benzoic acid methyl ester 
• 232275-49-9 methyl 4-amino-2,6-dichlorobenzoate 
• 1098619-73-8 2,6-dichloro-4-iodo-benzoic acid methyl ester 
• 1258298-01-9 2,6-dichloro-4-iodo-benzoic acid 
• 1258298-16-6 2,6-dichloro-4-iodo-benzoyl chloride 
• 1426833-40-0 2,6-dichloro-4-iodo-benzoic acid N'-(2-methyl-pyrido[2,3-b]pyrazin-3-yl)-hydrazide 
• 1426833-14-8 1-(2,6-dichloro-4-iodo-phenyl)-4-methyl-2,3,5,9,9b-pentaazacyclopenta[a]naphthalene 
• 852948-67-5 diethyl N-tert-butoxycarbonyl-[3,5-dichloro-4-(3'-iso-propyl-4'-methoxyphenoxy)phenylamino]methylphosphonate 
• 852948-65-3 [3,5-dichloro-4-(4'-hydroxy-3'-isopropylphenoxy)phenylamino]methylphosphonic acid 
• 1258298-20-2 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)-4-formylbenzamide 
• 1258298-19-9 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)-4-vinylbenzamide 
• 1258298-18-8 N-(2-bromopyridin-4-yl)-2,6-dichloro-4-vinylbenzamide 

Relevant academic research and scientific papers

MODULATORS OF THR-β AND METHODS OF USE THEREOF

Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IlIa, lIIb, IlIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.

PYRIDINE COMPOUNDS AND USES THEREOF

The present invention is directed to pyridine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psych

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors

Herein we report our lead optimization effort to identify potent, selective, and orally bioavailable TYK2 inhibitors, starting with lead molecule 3. We used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 3. Further optimization eventually led to compound 37 that showed good TYK2 enzyme and interleukin-12 (IL-12) cell potency, as well as acceptable cellular JAK1 and JAK2 selectivity and excellent oral exposure in mice. When tested in a mouse IL-12 PK/PD model, compound 37 showed statistically significant knockdown of cytokine interferon-γ (IFNγ), suggesting that selective inhibition of TYK2 kinase activity might be sufficient to block the IL-12 pathway in vivo.

IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4, R5 and R16 are defined herein, a pharmaceutical composition that includes a compound of Formulas Ia-Ib and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy.

JANUS KINASE INHIBITOR COMPOUNDS AND METHODS

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof

Novel Phosphinic Acid-Containing Thyromimetics

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs

Phosphonic acid (PA) thyroid hormone receptor (TR) agonists were synthesized to exploit the poor distribution of PA-based drugs to extrahepatic tissues and thereby to improve the therapeutic index. Nine PAs showed excellent TR binding affinities (TRβ

NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS

The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.

MODULATORS OF CELLULAR ADHESION

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).